AMB302
Phase 1An FGFR3-targeted ADC licensed to Biohaven in the US; its Korean Phase 1 plan was approved in April 2025.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has licensed several preclinical ADCs to global drugmakers, and licensed assets have entered Phase 1 in the US and Korea. Also seen: Global approvals · expansion
Roles often seen at this stageResearch & development · BD & licensing · Clinical & PV
An antibody-drug conjugate (ADC) developer spun off from Samsung Medical Center in 2018, using patient-derived cell and model platforms; listed on KOSDAQ in December 2025.
An FGFR3-targeted ADC licensed to Biohaven in the US; its Korean Phase 1 plan was approved in April 2025.
A solid-tumour ADC licensed to Boehringer Ingelheim in a deal worth up to USD 991 million; US FDA cleared its Phase 1 IND in June 2026.
A ROR1-targeted ADC co-developed with and licensed to SK Plasma, in IND-enabling preclinical studies.
ODS025, licensed to Boehringer Ingelheim, received US FDA clearance of its Phase 1 IND.
Listed on the KOSDAQ market.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.